Verona Pharma Plc Stock Performance

VRNA Stock  USD 34.98  1.05  3.09%   
On a scale of 0 to 100, Verona Pharma holds a performance score of 20. The entity has a beta of 2.06, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Verona Pharma will likely underperform. Please check Verona Pharma's skewness, and the relationship between the potential upside and rate of daily change , to make a quick decision on whether Verona Pharma's existing price patterns will revert.

Risk-Adjusted Performance

20 of 100

 
Weak
 
Strong
Solid
Compared to the overall equity markets, risk-adjusted returns on investments in Verona Pharma PLC are ranked lower than 20 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak basic indicators, Verona Pharma sustained solid returns over the last few months and may actually be approaching a breakup point. ...more

Actual Historical Performance (%)

One Day Return
3.09
Five Day Return
5.71
Year To Date Return
85.96
Ten Year Return
159.11
All Time Return
159.11
1
Disposition of 3736 shares by Mark Hahn of Verona Pharma at 3.25 subject to Rule 16b-3
08/13/2024
2
Nuance Pharma completes recruitment for ENHANCE-CHINA, the phase 3 clinical trial of ensifentrine for the maintenance treatment of COPD
09/11/2024
3
Verona Pharma Receives New Coverage from Analysts at Wells Fargo Company
10/07/2024
4
Wall Street Analysts Think Verona Pharma Could Surge 25.25 percent Read This Before Placing a Bet
10/11/2024
5
Disposition of 249728 shares by Mark Hahn of Verona Pharma at 4.3807 subject to Rule 16b-3
10/18/2024
6
Disposition of 159344 shares by Mark Hahn of Verona Pharma at 4.3849 subject to Rule 16b-3
10/22/2024
7
Verona Pharma CFO Mark Hahn sells shares worth 2.3 million
10/23/2024
8
Disposition of 140000 shares by David Zaccardelli of Verona Pharma at 4.3773 subject to Rule 16b-3
10/24/2024
9
Recent Price Trend in Verona Pharma is Your Friend, Heres Why
10/25/2024
10
Acquisition by Andrew Fisher of 300000 shares of Verona Pharma subject to Rule 16b-3
10/30/2024
11
Verona Pharma PLC Q3 2024 Earnings Report Preview What To Expect
11/01/2024
Begin Period Cash Flow227.8 M
Free Cash Flow-50.4 M
  

Verona Pharma Relative Risk vs. Return Landscape

If you would invest  2,096  in Verona Pharma PLC on August 6, 2024 and sell it today you would earn a total of  1,402  from holding Verona Pharma PLC or generate 66.89% return on investment over 90 days. Verona Pharma PLC is currently generating 0.853% in daily expected returns and assumes 3.2127% risk (volatility on return distribution) over the 90 days horizon. In different words, 28% of stocks are less volatile than Verona, and 83% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
  Expected Return   
       Risk  
Given the investment horizon of 90 days Verona Pharma is expected to generate 4.88 times more return on investment than the market. However, the company is 4.88 times more volatile than its market benchmark. It trades about 0.27 of its potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly 0.18 per unit of risk.

Verona Pharma Market Risk Analysis

Today, many novice investors tend to focus exclusively on investment returns with little concern for Verona Pharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Verona Pharma PLC, and traders can use it to determine the average amount a Verona Pharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.

Sharpe Ratio = 0.2655

Best PortfolioBest Equity
Good Returns
Average Returns
Small ReturnsVRNA
CashSmall RiskAverage RiskHigh RiskHuge Risk
Negative Returns

Estimated Market Risk

 3.21
  actual daily
28
72% of assets are more volatile

Expected Return

 0.85
  actual daily
16
84% of assets have higher returns

Risk-Adjusted Return

 0.27
  actual daily
20
80% of assets perform better
Based on monthly moving average Verona Pharma is performing at about 20% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Verona Pharma by adding it to a well-diversified portfolio.

Verona Pharma Fundamentals Growth

Verona Stock prices reflect investors' perceptions of the future prospects and financial health of Verona Pharma, and Verona Pharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Verona Stock performance.

About Verona Pharma Performance

By analyzing Verona Pharma's fundamental ratios, stakeholders can gain valuable insights into Verona Pharma's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Verona Pharma has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Verona Pharma has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.18)(0.19)
Return On Capital Employed(0.23)(0.24)
Return On Assets(0.18)(0.19)
Return On Equity(0.22)(0.23)

Things to note about Verona Pharma PLC performance evaluation

Checking the ongoing alerts about Verona Pharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Verona Pharma PLC help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Verona Pharma PLC appears to be risky and price may revert if volatility continues
The company reported the previous year's revenue of 458 K. Net Loss for the year was (54.58 M) with profit before overhead, payroll, taxes, and interest of 112 K.
Verona Pharma PLC currently holds about 111.51 M in cash with (50.42 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.83.
Verona Pharma PLC has a frail financial position based on the latest SEC disclosures
Over 93.0% of the company outstanding shares are owned by institutional investors
Latest headline from gurufocus.com: Verona Pharma PLC Q3 2024 Earnings Report Preview What To Expect
Evaluating Verona Pharma's performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Verona Pharma's stock performance include:
  • Analyzing Verona Pharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
  • Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Verona Pharma's stock is overvalued or undervalued compared to its peers.
  • Examining Verona Pharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
  • Evaluating Verona Pharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Verona Pharma's management team can help you assess the Company's leadership.
  • Pay attention to analyst opinions and ratings of Verona Pharma's stock. These opinions can provide insight into Verona Pharma's potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating Verona Pharma's stock performance is not an exact science, and many factors can impact Verona Pharma's stock market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.

Complementary Tools for Verona Stock analysis

When running Verona Pharma's price analysis, check to measure Verona Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Verona Pharma is operating at the current time. Most of Verona Pharma's value examination focuses on studying past and present price action to predict the probability of Verona Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Verona Pharma's price. Additionally, you may evaluate how the addition of Verona Pharma to your portfolios can decrease your overall portfolio volatility.
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators